Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase I trial of a new antiangiogenic agent from Daiichi

Sep. 13, 1996

Antiangiogenic eponemycin analogues

Sep. 13, 1996

The Liposome Company prepares and formulates new taxanes

Sep. 13, 1996

Improved camptothecin derivatives

Sep. 13, 1996

New multidrug resistance modulators

Sep. 6, 1996

Otsuka claims agents for cancer metastasis

Sep. 6, 1996

Promising results for lung cancer gene therapy

Sep. 6, 1996

Banyu discloses natural anticancer compounds

Sep. 6, 1996

Anticancer benzodiazepines from Genentech

Sep. 6, 1996

alpha1-Adrenoceptor antagonist effective in suppressing prostate cancer growth

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.